ISOFLURANE USP LIQUID

Land: Canada

Sprog: engelsk

Kilde: Health Canada

Aktiv bestanddel:

ISOFLURANE

Tilgængelig fra:

ABBVIE CORPORATION

ATC-kode:

N01AB06

INN (International Name):

ISOFLURANE

Dosering:

99.9%

Lægemiddelform:

LIQUID

Sammensætning:

ISOFLURANE 99.9%

Indgivelsesvej:

INHALATION

Enheder i pakken:

100ML/250ML

Recept type:

Prescription

Terapeutisk område:

INHALATION ANESTHETICS

Produkt oversigt:

Active ingredient group (AIG) number: 0114368001; AHFS:

Autorisation status:

CANCELLED POST MARKET

Autorisation dato:

2016-03-21

Produktets egenskaber

_ISOFLURANE Product Monograph _
_Page 1 of 28 _
_Date of Revision: December 5, 2017 and Control No.210900 _
PRODUCT MONOGRAPH
PR
ISOFLURANE USP
(isoflurane, USP)
volatile liquid (> 99.9% v/v isoflurane)
_ _
Inhalation Anesthetic
_ _
Date of Preparation:
October 5, 1998
Date of Previous Revision:
July 18, 2014
AbbVie Corporation
Date of Revision:
8401 Trans-Canada Highway
February 15, 2018
St-Laurent, Qc, Canada, H4S 1Z1
Submission Control No: 210900
_ISOFLURANE Product Monograph _
_Page 2 of 28 _
_Date of Revision: December 5, 2017 and Control No.210900 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE
REACTIONS....................................................................................................9
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE.................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
............................................................16
STORAGE AND STABILITY
..........................................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................18
PART II: SCIENTIFIC INFORMATION
...............................................................................19
PHARMACEUTICAL
INFORMATION....................